Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?
12:58pm, Sunday, 29'th May 2022 MarketWatch
Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.
3 Dividend Stocks You Can Buy and Hold Forever
11:31am, Sunday, 29'th May 2022 The Motley Fool
Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.
3 Dividend Stocks You Can Buy and Hold Forever
07:31am, Sunday, 29'th May 2022
Their strong underlying businesses should keep the quarterly payouts flowing to shareholders.
Is This Dividend Growth Stock a Buy?
02:37pm, Friday, 27'th May 2022 The Motley Fool
Eli Lilly has especially crushed the S&P 500 index year to date.
3 Reasons to Buy and Hold This Dividend Stock
02:00pm, Friday, 27'th May 2022 The Motley Fool
Amgen's 3.1% dividend yield is nearly double the S&P 500's -- and that's not the only thing to like about the stock.
Is This Dividend Growth Stock a Buy?
10:37am, Friday, 27'th May 2022
Eli Lilly has especially crushed the S&P 500 index year to date.
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
05:30pm, Thursday, 26'th May 2022 Benzinga
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
02:20pm, Thursday, 26'th May 2022
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
Executives Sell Around $207M Of 5 Stocks
12:10pm, Wednesday, 25'th May 2022 Benzinga
Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it indicates their concern in the company’s prospects or
3 Recession-Proof Stocks To Protect Your Portfolio From Fed-Induced Turmoil
09:38am, Wednesday, 25'th May 2022 Investing.com
Why This FDA Approval Is a Game Changer for Eli Lilly
02:53pm, Tuesday, 24'th May 2022 The Motley Fool
It could mean billions in revenue for the company.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
01:39pm, Tuesday, 24'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Eli Lilly and AstraZeneca Are the Lowest Spenders on Dividends, Buybacks
11:03am, Tuesday, 24'th May 2022
Share buybacks and dividends among large drug makers reached a five-year high in 2021 as spending climbed to about $110 billion, according to an analysis by pharma consulting group Evaluate Vantage.
Eli Lilly and Company (LLY) Management Presents at UBS Global Healthcare Conference (Transcript)
10:53am, Tuesday, 24'th May 2022
Eli Lilly and Company (NYSE:LLY ) UBS Global Healthcare Conference May 24, 2022 8:30 AM ET Company Participants Mike Mason - President of Lilly Diabetes Conference Call Participants Colin Bristow - UB
Why This FDA Approval Is a Game Changer for Eli Lilly
10:53am, Tuesday, 24'th May 2022
It could mean billions in revenue for the company.
